ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240

ALBI score and outcomes in patients with hepatocellular carcinoma: analysis of the randomized controlled trial KEYNOTE-240

Aims: This post hoc analysis evaluated albumin/bilirubin (ALBI) score, an objective measure of liver function, in patients receiving pembrolizumab plus best supportive care (BSC) compared with placebo plus BSC in the KEYNOTE-240 study. Methods: Patients with confirmed hepatocellular carcinoma (HCC)...

Full description

Bibliographic Details
Main Authors: Arndt Vogel, Philippe Merle, Chris Verslype, Richard S. Finn, Andrew X. Zhu, Ann-Lii Cheng, Stephen Lam Chan, Thomas Yau, Baek-Yeol Ryoo, Jennifer Knox, Bruno Daniele, Shukui Qin, Ziwen Wei, Yanna Miteva, Usha Malhotra, Abby B. Siegel, Masatoshi Kudo
Format: Article
Language:English
Published: SAGE Publishing 2021-09-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211039928

Internet

https://doi.org/10.1177/17588359211039928

Similar Items